Equities analysts forecast that HTG Molecular Diagnostics Inc (NASDAQ:HTGM) will report earnings per share of ($0.11) for the current fiscal quarter, according to Zacks Investment Research. Two analysts have issued estimates for HTG Molecular Diagnostics’ earnings, with estimates ranging from ($0.13) to ($0.08). HTG Molecular Diagnostics reported earnings per share of ($0.07) during the same quarter last year, which suggests a negative year-over-year growth rate of 57.1%. The business is expected to issue its next quarterly earnings results on Thursday, March 5th.

On average, analysts expect that HTG Molecular Diagnostics will report full year earnings of ($0.56) per share for the current financial year, with EPS estimates ranging from ($0.63) to ($0.52). For the next year, analysts expect that the company will post earnings of ($0.38) per share, with EPS estimates ranging from ($0.52) to ($0.30). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of sell-side research firms that that provide coverage for HTG Molecular Diagnostics.

HTG Molecular Diagnostics (NASDAQ:HTGM) last announced its quarterly earnings data on Tuesday, November 12th. The medical research company reported ($0.15) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.16) by $0.01. The firm had revenue of $5.41 million during the quarter, compared to analysts’ expectations of $5.63 million. HTG Molecular Diagnostics had a negative return on equity of 88.60% and a negative net margin of 76.97%.

Several brokerages have weighed in on HTGM. ValuEngine raised HTG Molecular Diagnostics from a “sell” rating to a “hold” rating in a report on Tuesday, December 3rd. Zacks Investment Research cut HTG Molecular Diagnostics from a “hold” rating to a “sell” rating in a report on Thursday. HC Wainwright restated a “buy” rating and set a $2.00 price objective on shares of HTG Molecular Diagnostics in a research report on Tuesday. Craig Hallum set a $3.00 price target on HTG Molecular Diagnostics and gave the company a “buy” rating in a research report on Friday, September 27th. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of HTG Molecular Diagnostics in a research report on Friday, October 18th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and four have assigned a buy rating to the company. The company currently has a consensus rating of “Buy” and an average target price of $3.13.

NASDAQ HTGM traded down $0.04 during midday trading on Friday, hitting $0.62. The company had a trading volume of 827,501 shares, compared to its average volume of 509,695. The company has a market capitalization of $35.79 million, a PE ratio of -1.06 and a beta of 1.56. The company has a current ratio of 5.21, a quick ratio of 5.07 and a debt-to-equity ratio of 0.34. The firm has a 50-day moving average price of $0.70 and a 200-day moving average price of $0.89. HTG Molecular Diagnostics has a twelve month low of $0.56 and a twelve month high of $3.24.

Hedge funds have recently added to or reduced their stakes in the company. Citadel Advisors LLC grew its holdings in shares of HTG Molecular Diagnostics by 153.9% in the second quarter. Citadel Advisors LLC now owns 38,525 shares of the medical research company’s stock valued at $64,000 after acquiring an additional 23,351 shares in the last quarter. BlackRock Inc. grew its holdings in shares of HTG Molecular Diagnostics by 504.3% in the second quarter. BlackRock Inc. now owns 405,837 shares of the medical research company’s stock valued at $673,000 after acquiring an additional 338,681 shares in the last quarter. Vanguard Group Inc. grew its holdings in shares of HTG Molecular Diagnostics by 20.0% in the second quarter. Vanguard Group Inc. now owns 1,453,160 shares of the medical research company’s stock valued at $2,413,000 after acquiring an additional 242,497 shares in the last quarter. Finally, Perkins Capital Management Inc. grew its holdings in shares of HTG Molecular Diagnostics by 297.1% in the third quarter. Perkins Capital Management Inc. now owns 2,353,153 shares of the medical research company’s stock valued at $1,564,000 after acquiring an additional 1,760,533 shares in the last quarter. 38.94% of the stock is owned by institutional investors.

About HTG Molecular Diagnostics

HTG Molecular Diagnostics, Inc a commercial stage life sciences company, focuses on the precision medicine. The company offers instrumentation (or platforms); consumables comprising assay kits; and software analytics that automate sample processing and profiles various molecular targets. Its platforms generate a molecular profiling library for detection using next-generation sequencing.

Further Reading: What are the benefits of a portfolio tracker?

Get a free copy of the Zacks research report on HTG Molecular Diagnostics (HTGM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for HTG Molecular Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HTG Molecular Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.